Skip to content

Adjunctive Benefit of a Xenogenic Collagen Matrix

Adjunctive Benefit of a Xenogenic Collagen Matrix Associated With Coronally Advanced Flap for Treating Multiple Gingival Recessions

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03833765
Enrollment
24
Registered
2019-02-07
Start date
2012-11-28
Completion date
2017-07-17
Last updated
2019-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingival Recession

Keywords

gingival recession

Brief summary

The present CONSORT-based randomized clinical trial is to assess the adjunctive benefit of a xenogenic collagen matrix in combination with a coronal advanced flap with respect to a coronal advanced flap alone in the treatment of multiple gingival recession defects in adult population.

Detailed description

This is a single-centre, superiority, double blind clinical trial, with balanced randomisation and parallel two groups design. The 2 groups will be: 1. CAF combined with XCM; 2. CAF alone. The objective is therefore to assess the adjunctive benefit of a xenogenic collagen matrix in combination with a coronal advanced flap. The primary endpoint is the mean recession reduction after 6 and 12 months post treatment. The secondary endpoints are: Percentage of complete root coverage after 6 and 12 month; Thickness of soft tissue over the root after 6 and 12 month; Recession width after 6 and 12 month; KT width; Patients satisfaction. The following Inclusion Criteria have to be satisfied: patient (male or female) must be 18 years or older, not pregnant, and candidate for buccal root coverage procedure in the upper jaw; recession defects have to be AAA or ABA (according to Rotundo et al classification), with at least 2 adjacent RC with ≥ 2 mm RC depth and root abrasion depth less than 1 mm; Patient shows sufficient plaque control (FMPS ≤ 20%) and acceptable bleeding score(FMBS ≤ 20%); Teeth intended to treat are in the region 1 - 5; patient has to be able to comply with the study-related procedures such as exercising good oral hygiene and attending all follow-up procedures; patient is able to fully understand the nature of the proposed surgery and is able to provide a signed informed consent. Randomisation: Computer-generated blocked for each centre, with allocation concealment by opaque sequentially numbered sealed envelopes. Blinding: Patients and outcome assessor blind to group assignment. Sample size: Based on a formula for cluster design to detect a difference between treatments of 1 mm in recession reduction (standard deviation of 0.93 mm - Woodyard et al. 2004) with a two-side 5% significance level, a power of 90%, a mean number of treated teeth per patient of 2.92, an intraclass correlation coefficient of 0.35, a sample size of 24 patients per treatment will be necessary.

Interventions

PROCEDURECAF+XCM

After flap elevation according to the Coronally Advanced Flap procedure for multiple recession defects, a Xenogeneic Collagen Matrix was applied and then covered by the flap.

PROCEDURECAF alone

Coronally Advanced Flap procedure alone was performed to treat multiple recession defects

Sponsors

Geistlich Pharma AG
CollaboratorINDUSTRY
Roberto Rotundo
Lead SponsorINDIV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

single-centre, superiority, double blind clinical trial, with balanced randomisation and parallel two groups design according to CONSORT statement

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. The patient (male or female) must be 18 years or older 2. Presence of gingival recessions in the upper jaw, involving teeth from central incisor to first molar 3. Gingival recessions on at least 2 adjacent teeth with a minimal depth of 2mm and detectable cemento-enamel junction (CEJ) (abrasion step \<1mm) 4. The patient is able to comply with the study-related procedures such as exercising good oral hygiene and attending all follow-up procedures 5. Full Mouth Plaque (FMPS) and Bleeding (FMBS) Score \<20% 6. The patient is able to fully understand the nature of the proposed surgery and is able to provide a signed informed consent

Exclusion criteria

1. Smoker patients 2. Pregnant patients 3. Patients affect by uncontrolled diabetes 4. General contraindications for dental and/or surgical treatment are present 5. History of malignancy, radiotherapy, or chemotherapy for malignancy within the past 5 years 6. The patient is taking medications or having treatments which have an effect on mucosal healing in general (e.g. steroids, large doses of anti-inflammatory drugs, anticoagulation drugs) 7. The patient has a disease, which affects connective tissue metabolism (e.g. collagenases) 8. The patient is allergic to collagen 9. The patient is an abuser of alcohol or drug 10. Patients have participated in a clinical trial within the last six months 11. Presence of untreated periodontitis 12. Gingival recessions on molar teeth (excluding the first) or on malpositioned teeth 13. Presence of abrasion ≥ 1 mm or cervical restoration, with non-detectable CEJ

Design outcomes

Primary

MeasureTime frameDescription
Mean Recession Reduction12 monthsThe distance between CEJ and the free gingival margin (Rec depth) will be measured at baseline, 3, 6 and 12 months. The mean change will be then calculated.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026